CDT Overview

CDT Equity Inc., formerly Conduit Pharmaceuticals, Inc. is a data-driven biotech development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Through advanced co-crystallization and solidform technologies developed at its Cambridge facility, it is engaged in improving drug properties and has helped in extending the patent life of certain drugs by up to 20 years. Its pipeline includes candidates targeting inflammatory and autoimmune disorders, as well as idiopathic male infertility, dermatology and animal health. It applies proprietary algorithms utilizing AI-powered disease mapping to identify novel repurposing opportunities against a database of over 800 disease signatures. In addition, the Company has initiated pre-clinical in-vitro models to explore new indications, guided by AI-insights without human intervention.

Wall Street analysts forecast CDT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CDT is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

CDT Equity Inc revenue for the last quarter amounts to -21.16M USD, increased 502.22

CDT Equity Inc. EPS for the last quarter amounts to -5641000.00 USD, increased 47.94

CDT Equity Inc (CDT) has 4 emplpoyees as of May 21 2026.

Today CDT has the market capitalization of 5.98M USD.